Glutamate carboxypeptidase II (GCPII) is a membrane-bound metallopeptidase predominantly expressed in neural and prostatic tissues, with significantly elevated levels in prostate carcinoma that increase with tumor grade. Despite its significance as a target for imaging and therapy in prostate cancer, its physiological function in this tissue remains poorly understood. To help fill this knowledge gap, we developed an integrated approach combining proximity labeling technologies for proteomic profiling (horseradish peroxidase, µMap, and riboflavin tetraacetate labeling) with our previously established iBody platform, which targets GCPII with a small-molecule specific inhibitor with proven efficacy as a chemical probe. Proximity labeling proteomic experiments on U251 MG-GCPII cells were followed by mass spectrometry and statistical analysis of protein abundances obtained by label-free quantification. Additionally, selected identified proteins were further validated through Western blot analyses and GCPII pulldown assays using cell lysates. This work identifies a network of GCPII-associated proteins that are potentially involved in cancer metabolism, migration, invasiveness, progression, and immune evasion. Our novel proximity proteomics labeling strategy provides a low-background framework, efficient biotinylation, and enhanced target binding via the avidity effect. Among the approaches tested, riboflavin tetraacetate-based iBody labeling exhibited the highest precision, underscoring its potential for membrane protein interactome mapping.

Department of Biochemistry and Experimental Oncology 1st Faculty of Medicine Charles University U Nemocnice 5 Prague 128 00 Czech Republic

Department of Biomedical Polymers Institute of Macromolecular Chemistry Czech Academy of Sciences Heyrovského nám 2 Prague 160 00 Czech Republic

Institute of Organic Chemistry and Biochemistry Czech Academy of Sciences Flemingovo nám 542 2 Prague 160 00 Czech Republic

Zobrazit více v PubMed

Morland, C. & Nordengen, K. N-Acetyl-aspartyl-glutamate in brain health and disease. PubMed DOI PMC

Pinto, J. T. et al. Prostate-specific membrane antigen: a novel folate hydrolase in human prostatic carcinoma cells. PubMed

Perner, S. et al. Prostate-specific membrane antigen expression as a predictor of prostate cancer progression. PubMed DOI

Minner, S. et al. High level PSMA expression is associated with early PSA recurrence in surgically treated prostate cancer. PubMed DOI

Chang, S. S., Reuter, V. E., Heston, W. D. & Gaudin, P. B. Comparison of anti-prostate-specific membrane antigen antibodies and other immunomarkers in metastatic prostate carcinoma. PubMed DOI

Chang, S. S. et al. Prostate-specific membrane antigen is produced in tumor-associated neovasculature. PubMed

Benešová, M. et al. Preclinical evaluation of a tailor-made DOTA-conjugated Psma inhibitor with optimized linker moiety for imaging and endoradiotherapy of prostate cancer. PubMed DOI

Hennrich, U. & Eder, M. [(177)Lu]Lu-PSMA-617 (Pluvicto(TM)): the first FDA-approved radiotherapeutical for treatment of prostate cancer. PubMed PMC

Novartis in

Bauer, N. C., Doetsch, P. W. & Corbett, A. H. Mechanisms regulating protein localization. PubMed DOI

Roux, K. J., Kim, D. I., Burke, B. & May, D. G. BioID: A screen for protein-protein interactions. PubMed PMC

Rhee, H. W. et al. Proteomic mapping of mitochondria in living cells via spatially restricted enzymatic tagging. PubMed DOI PMC

Honke, K., Miyagawa-Yamaguchi, A. & Kotani, N. The EMARS reaction for proximity labeling. PubMed DOI

Rees, J. S., Li, X. W., Perrett, S., Lilley, K. S. & Jackson, A. P. Selective proteomic proximity labeling assay using tyramide (SPPLAT): a quantitative method for the proteomic analysis of localized membrane-bound protein clusters. PubMed

Geri, J. B. et al. Microenvironment mapping via Dexter energy transfer on immune cells. PubMed DOI PMC

Oslund, R. et al. Athens, Greece,. in

Hope, T. O. et al. Targeted proximity-labelling of protein tyrosines via flavin-dependent photoredox catalysis with mechanistic evidence for a radical-radical recombination pathway. PubMed DOI PMC

Bayer & Wilchek, E. A. Application of avidin-biotin technology to affinity-based separations. PubMed DOI

Tyanova, S. et al. The perseus computational platform for comprehensive analysis of (prote)omics data. PubMed DOI

Oakley, J. V. et al. Radius measurement via super-resolution microscopy enables the development of a variable radii proximity labeling platform. PubMed DOI PMC

Kim, D. I. et al. Probing nuclear pore complex architecture with proximity-dependent biotinylation. PubMed DOI PMC

Haag, R. & Kratz, F. Polymer therapeutics: concepts and applications. PubMed DOI

Šácha, P. et al. iBodies: modular synthetic antibody mimetics based on hydrophilic polymers decorated with functional moieties. PubMed DOI PMC

Dvořáková, P. et al. Inhibitor-decorated polymer conjugates targeting fibroblast activation protein. PubMed DOI

Šimon, P. et al. Identification of protein targets of bioactive small molecules using randomly photomodified probes. PubMed DOI

Blažková, K. et al. The development of a high-affinity conformation-sensitive antibody mimetic using a biocompatible copolymer carrier (iBody). PubMed DOI PMC

Sansee, A. et al. Iridium-based polymeric multifunctional imaging tools for biochemistry. PubMed

Neburkova, J. et al. Inhibitor-GCPII interaction: selective and robust system for targeting cancer cells with structurally diverse nanoparticles. PubMed DOI

Liu, H. et al. Constitutive and antibody-induced internalization of prostate-specific membrane antigen. PubMed

Knutson, S. D., Buksh, B. F., Huth, S. W., Morgan, D. C. & MacMillan, D. W. C. Current advances in photocatalytic proximity labeling. PubMed DOI PMC

Kang, M. G. & Rhee, H. W. Molecular spatiomics by proximity labeling. PubMed DOI PMC

Trowbridge, A. D. et al. Small molecule photocatalysis enables drug target identification via energy transfer. PubMed DOI PMC

Ducker, G. S. & Rabinowitz, J. D. One-carbon metabolism in health and disease. PubMed DOI PMC

Hassanein, M. et al. SLC1A5 mediates glutamine transport required for lung cancer cell growth and survival. PubMed DOI PMC

Sakata, T. et al. L-type amino-acid transporter 1 as a novel biomarker for high-grade malignancy in prostate cancer. PubMed DOI

Bhutia, Y. D., Babu, E., Ramachandran, S. & Ganapathy, V. Amino acid transporters in cancer and their relevance to glutamine addiction: novel targets for the design of a new class of anticancer drugs. PubMed DOI

Yayan, J., Franke, K. J., Berger, M., Windisch, W., Rasche, K. & ; ; Adhesion, Metastasis, and Inhibition of cancer cells. PubMed DOI PMC

Jiang, X., Zhang, J. & Huang, Y. Tetraspanins in cell migration. PubMed DOI PMC

Moore, C. J. & Winder, S. J. Dystroglycan versatility in cell adhesion: a Tale of multiple motifs. PubMed DOI PMC

Zhang, Y., Liu, Q., Yang, S. & Liao, Q. CD58 immunobiology at a glance. PubMed DOI PMC

Ward, Y. et al. LPA receptor heterodimerizes with CD97 to amplify LPA-initiated RHO-dependent signaling and invasion in prostate cancer cells. PubMed DOI PMC

Munger, J. S. & Sheppard, D. Cross talk among TGF-β signaling pathways, integrins, and the extracellular matrix. PubMed DOI PMC

Xie, P. et al. DCBLD2 affects the development of colorectal cancer via Emt and angiogenesis and modulates 5-fu drug resistance. PubMed DOI PMC

Pach, E. et al. Extracellular matrix remodeling by fibroblast-mmp14 regulates melanoma growth. PubMed PMC

Pang, X. et al. Targeting integrin pathways: mechanisms and advances in therapy. PubMed DOI PMC

Conway, R. E. et al. Prostate-specific membrane antigen regulates angiogenesis by modulating integrin signal transduction. PubMed DOI PMC

Caromile, L. A. et al. PSMA redirects cell survival signaling from the MAPK to the PI3K-AKT pathways to promote the progression of prostate cancer. PubMed PMC

Perico, M. E. et al. Prostate-specific membrane antigen (PSMA) assembles a macromolecular complex regulating growth and survival of prostate cancer cells in vitro and correlating with progression in vivo. PubMed DOI PMC

Bařinka, C., Rojas, C., Slusher, B. & Pomper, M. Glutamate carboxypeptidase II in diagnosis and treatment of neurologic disorders and prostate cancer. PubMed DOI PMC

Evans, J. C., Malhotra, M., Cryan, J. F. & O’Driscoll, C. M. The therapeutic and diagnostic potential of the prostate specific membrane antigen/glutamate carboxypeptidase II (PSMA/GCPII) in cancer and neurological disease. PubMed DOI PMC

Nguyen, T. et al. Uncovering the role of n-acetyl-aspartyl-glutamate as a glutamate reservoir in cancer. PubMed PMC

Sigismund, S., Avanzato, D. & Lanzetti, L. Emerging functions of the EGFR in cancer. PubMed DOI PMC

Schunemann, D. P. et al. Glutamate promotes cell growth by EGFR signaling on U-87MG human glioblastoma cell line. PubMed DOI

Sitcheran, R., Comb, W. C., Cogswell, P. C. & Baldwin, A. S. Essential role for epidermal growth factor receptor in glutamate receptor signaling to NF-kappaB. PubMed DOI PMC

Hassn Mesrati, M., Syafruddin, S. E., Mohtar, M. A. & Syahir, A. CD44: A multifunctional mediator of cancer progression. PubMed PMC

Mo, X. T. et al. CD109 mediates tumorigenicity and cancer aggressiveness via regulation of EGFR and STAT3 signalling in cervical squamous cell carcinoma. PubMed DOI PMC

Kim, H. et al. Transferrin receptor-mediated iron uptake promotes colon tumorigenesis. PubMed DOI PMC

Manca, M. A. et al. Association of HLA-A*11:01, -A*24:02, and -B*18:01 with prostate cancer risk: a case-control study. PubMed PMC

Zhao, Y., Malinauskas, T., Harlos, K. & Jones, E. Y. Structural insights into the Inhibition of Wnt signaling by cancer antigen 5T4/Wnt-activated inhibitory factor 1. PubMed DOI PMC

Deborde, S. et al. Schwann cells induce cancer cell dispersion and invasion. PubMed DOI PMC

Gutiérrez Fuster, R., León, A., Aparicio, G. I., Brizuela Sotelo, F. & Scorticati, C. Combined additive effects of neuronal membrane glycoprotein GPM6a and the intercellular cell adhesion molecule ICAM5 on neuronal morphogenesis. PubMed DOI